GMR Solutions Q3 2026 earnings

GMRS · 2026-11-09 16:52 AMC ET · 8-K on SEC

Revenue and net income grew in Q3, with net income up 81.7% to $135.6 million, despite weather-related pressure and inflationary costs.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$1,595.6M+5.9%+7.0%Ex. 99.1, income statement
EPS (GAAP)$0.56+700.0%+314.3%Ex. 99.1, income statement
EPS (adjusted)$0.57+714.3%+321.4%Ex. 99.1, income statement
Net income$135.6M+81.7%+481.0%Ex. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 13.6% (prior 13.8%, change -0.2 pp)
  • Operating expenses $1,334.1M (+3.3% YoY)
  • One-offs in the quarter Stock-based compensation: $1.6M (vs $5.8M YoY); Professional fees and other expenses for non-recurring matters: $11.5M (vs $4.5M YoY); Debt refinancing fees paid to (received from) third parties: $3.4M (vs $39.1M YoY); Loss on debt extinguishment: $5.7M; Impairment of assets held for sale and other investments: $14.1M (Nine Months); (Gain) loss on divestiture of businesses: $3.8M (Nine Months)
  • Effective tax rate 43.4% (prior 28.5%, year-to-date 32.7%)
  • Non-GAAP bridge Adds back management fees, stock-based compensation, professional fees for non-recurring matters, and debt refinancing fees.

KPIs

MetricActualPrior quarterPrior yearChange
Revenue per transportNot statedNot statedNot statedNot stated
Critical care intervention frequencyEvery 87 secondsEvery 88 secondsNot statedFaster
Patient encountersNot statedNot statedNot statedNot stated

Guidance

MetricGuidePrior guideChange
Net revenue$5.9B - $6.05B$5.89B - $6.18B-0.1% - -2.1%
Adjusted EBITDA$1.135B - $1.195B$1.135B - $1.195BNo change
Cash used for net capital expenditures and aircraft financing as a percent of net revenue5.2% - 5.4%5.1% - 5.3%+0.1% - +0.1 pp

What drove it

  • Revenue story Revenue increased 5.9% to $1,595.6 million, driven by growth in core emergent services and Nurse Navigation, despite weather-related pressure on flight activity.
  • EPS story EPS growth was driven by higher net income, improved operating margins, and a lower tax rate, partially offset by higher interest expense.
  • One-off check Stock-based compensation decreased significantly year-over-year to $1.6 million, while debt refinancing fees decreased to $3.4 million.

The good

  • Revenue growth of 5.9% despite weather-related pressure and inflationary costs.
  • Net income increased 81.7% to $135.6 million.
  • Adjusted EBITDA increased 4.2% to $356.6 million.

The bad

  • Operating expenses increased 3.3% year-over-year.
  • Interest expense increased 36.5% year-over-year to $68.1 million.
  • Weather-related pressure on flight activity and higher fuel costs.

The ugly

  • none

Open questions

  • The filing does not disclose the specific revenue per transport metric.
  • The filing does not disclose the specific patient encounter count.
Full release

GMR Solutions (GMRS) earnings release, November 9, 2026

GMR Solutions Inc. (GMRS) · Form 8-K, Item 2.02 · Filed · SEC filing

​

​

GMR Solutions Inc. Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Updated Full Year 2026 Guidance

LEWISVILLE, Texas (November 9, 2026) — GMR Solutions Inc. (“GMR” or the “Company”) (NYSE: GMRS), the nation’s largest provider of emergency medical services (“EMS”), today announced financial results for the three and nine months ended September 30, 2026, and updated its full year 2026 financial guidance.

“The third quarter showcased the resiliency that is inherent in GMR’s scale, national footprint, and integrated model,” said Nick Loporcaro, Chairman and Chief Executive Officer. “Our ability to serve patients across a broad range of operations and geographies helped us navigate weather-related constraints and other external pressures while continuing to grow our core emergent services. Combined with the momentum we are seeing in Nurse Navigation and new market growth, these results reinforce our confidence in the strength of our platform and opportunities ahead.”

“We delivered strong financial performance in the third quarter, with revenue increasing 5.9% to $1,595.6 million, and net income increasing 81.7% to $135.6 million, despite weather-related pressure on flight activity, higher fuel and other inflationary costs, and the anticipated shift in payor mix,” said Brian Tierney, Chief Financial Officer. “Growth in our core emergent services, continued improvement in revenue per transport and disciplined cost management helped us absorb these headwinds while continuing to invest in the business and strengthen our financial position.”

Third Quarter 2026 Financial Highlights

​¹

​

Key Financials

​

​

Business Metrics

​

​

​²

​

Full Year 2026 Financial Guidance

​

GMR is updating the following guidance for the full year 2026:

​

​

​

Webcast and Conference Call Details

​

The Company will host a conference call tomorrow, November 10, 2026, at 8:00 a.m. Eastern Time. Investors can access the live call by joining the following link https://events.q4inc.com/attendee/164439003.

​

An archived webcast of the event will be available on the “Events & Presentations” section of the GMR website at https://investors.globalmedicalresponse.com/. The Company has posted supplemental information on the results that it will reference during the conference call. The supplemental information can be found under the “Financials” tab on the Company’s investor relations page. Following the live event, replays will be available via webcast for one year at https://investors.globalmedicalresponse.com/.

​

About Global Medical Response

​

GMR is the nation’s largest provider of EMS, delivering EMS and other essential out-of-hospital care in rural and urban communities that represent more than 60% of the U.S. population. As the only national, fully integrated, air and ground EMS provider, GMR operates in approximately 1,400 counties across the country. A recognized innovator, GMR develops new solutions to meet evolving industry needs and expand access to high-quality care. With approximately 34,000 team members, GMR supports roughly 5.5 million patient encounters annually and performs a critical care intervention every 87 seconds. Its family of solutions includes ambulance EMS provider American Medical Response, as well as multiple air EMS organizations including Air Evac Lifeteam, REACH Air Medical Services, Guardian Flight, Med-Trans Corporation, and AirMed International.

​

We may use our website (www.globalmedicalresponse.com), Facebook page (www.facebook.com/GlobalMedicalResponse), X (Twitter) (www.x.com/GMR_Social), LinkedIn (www.linkedin.com/company/Global-Medical-Response), and Instagram (www.instagram.com/Global_Medical_Response), accounts as channels of distribution of company information. The information we post through these channels may be deemed material. Accordingly, investors should monitor these channels, in addition to following our press releases, Securities and Exchange Commission (“SEC”) filings and public conference calls and webcasts. In addition, you may automatically receive email alerts and other information about the Company when you enroll your email address by visiting the “Investor Email Alerts” section of our website at https://investors.globalmedicalresponse.com/resources/investor-email-alerts/default.aspx. The contents of our website, any alerts and social media channels are not, however, a part of this press release.

​

Financial statements

Income Statement

Three Months Ended — Key Financials (in thousands)

Three Months Ended – September 30, – 2026 – (Unaudited)Three Months Ended – September 30, – 2025 – (Unaudited)%Nine Months Ended – September 30, – 2026 – (Unaudited)Nine Months Ended – September 30, – 2025 – (Unaudited)%
Net revenue1,595,5551,506,8685.9%4,543,4174,316,2865.3%
Net income135,55574,59981.7%213,613193,38410.5%
Adjusted EBITDA(1)356,557342,1194.2%946,145942,7530.4%

Income Statement

Range for the year ending — GMR is updating the following guidance for the full year 2026: (in millions)

Range for the year ending – December 31, 2026 – LowRange for the year ending – December 31, 2026 – High
Net revenue5,9006,050
Adjusted EBITDA(2)1,1351,195
Cash used for net capital expenditures and aircraft financing as a percent of net revenue5.2%5.4%

Income Statement

Three Months Ended — )

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Net revenue1,595,5551,506,8684,543,4174,316,286
Operating expenses:
Employee wages, benefits and taxes801,712773,6582,496,2402,251,033
Maintenance, fuel and other direct expenses150,034119,922405,071344,350
Insurance expense55,18657,214149,042142,167
Other operating expenses238,390225,158698,384661,872
Depreciation and amortization78,53173,366230,854221,000
Impairment of assets held for sale and other investments14,100
Acquisition, integration and other charges10,23140,97626,76846,332
Total operating expenses1,334,0841,290,2944,006,3593,680,854
Operating income261,471216,574537,058635,432
Interest expense, net68,062107,205228,084329,406
Loss on debt extinguishment5,7455,745
Equity in (earnings) losses of unconsolidated affiliates-1,272-226-2,171-2,800
Other (income) loss, net220-635-6,5498,911
Net income (loss) before income taxes194,461104,485317,694294,170
Income tax (benefit) expense58,90629,886104,081100,786
Net income (loss)135,55574,599213,613193,384
Net income (loss) available to common stockholders per share:
Basic1.690.220.991.06
Diluted0.560.070.310.32
Weighted-average common shares outstanding:
Basic80,102,05045,553,96862,997,92645,553,313
Diluted242,376,462148,330,947200,337,433148,619,004
Comprehensive income (loss):
Net income (loss)135,55574,599213,613193,384
Other comprehensive income (loss)
Unrealized holding gains (losses) on investments-1,734685-1,4211,524
Deferred income tax benefit (expense), net385-151315-337
Total other comprehensive income (loss), net of income tax-1,349534-1,1061,187
Comprehensive income (loss)134,20675,133212,507194,571

Income Statement

Three Months Ended — The following table reconciles net income to EBITDA and Adjusted EBITDA:

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 20252026 v. – 2025 ChangeNine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 20252026 v. – 2025 Change
Net income (loss)135,55574,59981.7213,613193,38410.5
Interest expense, net68,062107,205-36.5228,084329,406-30.8
Income tax provision (benefit)58,90629,88697.1104,081100,7863.3
Depreciation and amortization78,53173,3667230,854221,0004.5
EBITDA341,054285,05619.6776,632844,576-8
Management fees(1)2,705nm4,7218,116-41.8
Stock-based compensation(2)1,5515,762-73.1134,06211,3531,080.9
Professional fees and other expenses for non-recurring matters(3)11,4814,492155.634,62711,867191.8
Debt refinancing fees paid to (received from) third parties(4)3,36239,098-91.43,92139,470-90.1
Impairment of assets held for sale and other investments(5)nm14,100nm
Loss on debt extinguishment(6)5,745nm5,745nm
(Gain) loss on divestiture of businesses(7)nm3,837nm
Realized and unrealized (gain) loss, net(8)381-513-174.3-5,6476,489-187
Equity method investment (income) loss(9)-1,272-226462.8-2,171-2,800-22.5
Adjusted EBITDA356,557342,1194.2946,145942,7530.4

Income Statement

Three Months Ended — (Unaudited)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Diluted net income (loss) available to common stockholders per share (GAAP)0.560.070.310.32
Undeclared dividends on redeemable preferred stock(3)0.270.160.81
Loss on redemption of redeemable preferred stock(3)0.160.590.16
Management fees(4)0.020.020.05
Stock-based compensation(4)0.010.040.670.08
Professional fees and other expenses for non-recurring matters(4)0.050.030.170.08
Debt refinancing fees paid to (received from) third parties(4)0.010.260.020.27

Balance Sheet

September 30, — (Amounts in thousands, except share and par value amounts)

September 30, – 2026 – (unaudited)December 31, – 2025
Current assets:
Cash and cash equivalents297,987609,349
Insurance collateral85,47278,608
Accounts receivable, net1,249,2931,094,814
Spare parts, medical supplies and fuel128,877115,725
Prepaid expenses88,040105,014
Reinsurance recoverables112,71181,791
Other current assets53,93746,780
Total current assets2,016,3172,132,081
Property and equipment, net of accumulated depreciation of $1,351,267 and $1,223,603 at September 30, 2026 and December 31, 2025, respectively1,462,5481,361,278
Operating right-of-use assets224,519203,258
Finance right-of-use assets77,04685,030
Intangible assets, net1,155,8381,204,237
Goodwill2,180,5812,180,581
Other assets403,499315,580
Total assets7,520,3487,482,045
Current liabilities:
Accounts payable66,25960,047
Accrued wages, benefits and taxes299,660339,710
Accrued interest38,71375,655
Other accrued liabilities510,762363,160
Current portion of lease obligations76,13878,717
Current portion of long-term debt164,104147,140
Total current liabilities1,155,6361,064,429
Operating lease obligations193,227171,880
Finance lease obligations74,35974,943
Long-term debt4,096,0434,898,769
Deferred income taxes208,740209,067
Tax receivable agreement liability470,791
Insurance reserves362,664312,069
Other long-term liabilities50,619101,593
Total liabilities6,612,0796,832,750
Mezzanine equity:
Redeemable preferred stock445,140
Total mezzanine equity445,140
Stockholders’ equity:
Class A Common stock, $0.0001 par value, 1,200,000,000 and 200,000,000 shares authorized, 66,698,468 and 22,096,835 shares issued and outstanding, respectively, as of September 30, 2026 and December 31, 202572
Additional paid-in capital948,068456,466
Retained earnings (deficit)-45,879-259,492
Accumulated other comprehensive income (loss)6,0737,179
Total stockholders' equity (deficit)908,269204,155
Total liabilities, mezzanine equity and stockholders' equity7,520,3487,482,045

Cash Flow

Nine Months Ended — (Amounts in thousands, unaudited)

Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Cash flows from operating activities:
Net income (loss)213,613193,384
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities
Depreciation and amortization230,854221,000
Amortization of deferred financing costs and debt discount18,13411,236
Paid-in-kind interest on long-term debt22,450
Loss on debt extinguishment5,745
Impairment of assets held for sale and other investments14,100
(Gain) loss on divestiture of businesses3,837
Stock-based compensation expense142,6401,796
Liability classified stock awards-11,5699,557
Loss (gain) on disposal of property and equipment1,8228,435
Unrealized loss (gain) on marketable equity securities1,298270
Deferred income taxes-12-7
Other, net-9,0713,419
Changes in assets and liabilities, net of effects of acquisitions
Accounts receivable, net-154,479-112,187
Accounts payable6,2123,340
Accrued wages, benefits and taxes-40,67826,983
Accrued interest-36,942-5,930
Accrued liabilities84,041-50,216

Forward-Looking Statements

​

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect our current views with respect to, among other things, our operations and financial performance. Forward-looking statements include all statements that are not historical facts, including statements related to momentum in Nurse Navigation, market growth and our financial guidance. These forward-looking statements may relate to matters which include, but are not limited to, industries, business strategy, goals and expectations concerning our market position, future operations, margins, profitability, capital expenditures, liquidity and capital resources and other financial and operating information. In some cases, you can identify these forward-looking statements by the use of words such as “anticipate,” “assume,” “believe,” “can,” “continue,” “could,” “estimate,” “expect,” “foreseeable,” “future,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” “would,” the negative version of these words, or similar terms and phrases.³

​... (truncated)believe there is a reasonable basis for them. However, there can be no assurance that management’s expectations, beliefs, and projections will result or be achieved. Actual results may differ materially from these expectations due to changes in global, regional or local economic, business, competitive, market, regulatory and other factors, many of which are beyond our control. We believe that these factors include but are not limited to the following:⁴

​

These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included herein and in our filings with the SEC, including the information under the caption “Risk Factors” in GMR’s final prospectus (the “IPO Prospectus”) in connection with our initial public offering (the “IPO”), filed with the SEC and dated May 12, 2026, as well as GMR’s subsequent other filings with the SEC from time to time. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual results may vary in material respects from those projected in these forward-looking statements.

​

Any forward-looking statement made by us herein speaks only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included herein. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures, investments, or other strategic transactions we may make. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. For additional information on these and other factors that could cause GMR’s actual results to differ materially from expected results, please see our filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and on the “Investor Relations” tab of our website.

Non-GAAP Financial Measures

This press release contains “non-GAAP financial measures,” which are financial measures that either exclude or include amounts that are not excluded or included in the most directly comparable measures calculated and presented in accordance with GAAP. Specifically, we make use of the non-GAAP financial measures “EBITDA,” “Adjusted EBITDA,” and “Adjusted Diluted EPS.”

We provide non-GAAP financial information to enhance the understanding of our GAAP financial information and it should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure is presented along with the corresponding GAAP measure so as not to imply that more emphasis should be placed on the non-GAAP measure. We believe that providing these non-GAAP measures in addition to the GAAP measures allows management, investors and other users of our financial information to more fully and accurately assess performance. The non-GAAP financial information presented may be determined or calculated differently by other companies and may not be directly comparable to that of other companies.

​

EBITDA and Adjusted EBITDA

​

We define EBITDA as net income (loss) before interest expense, net, income tax provision (benefit), and depreciation and amortization. We define Adjusted EBITDA as EBITDA, as further adjusted to exclude management fees, stock-based compensation, professional fees and other expenses for non-recurring matters, debt refinancing fees paid to (received from) third parties and certain other items that we do not consider indicative of our ongoing operating performance.

​

Management uses EBITDA and Adjusted EBITDA to supplement GAAP measures of performance in the evaluation of the effectiveness of our business strategies, to make budgeting decisions, to establish and award discretionary annual incentive compensation, to report compliance with certain covenants in our debt agreements and to compare our performance against that of peer companies using similar measures. Moreover, we present EBITDA and Adjusted EBITDA because we believe that investors consider them to be important supplemental measures of our performance and believe these measures are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in our industry.

​⁵

​

Adjusted EBITDA is an analytical indicator used by management and the healthcare industry to evaluate company performance and allocate resources. Adjusted EBITDA should not be considered in isolation or as an alternative to net income (loss), cash flows from operations, investing or financing activities, or other financial statement data presented in the unaudited condensed consolidated financial statements as indicators of financial performance. Because Adjusted EBITDA is not a measure determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA as presented may not be comparable to other similarly titled measures of other companies and may not be comparable to similarly titled measures used in debt compliance calculations. Net income (loss) is the financial measure calculated and presented in accordance with GAAP that is most comparable to Adjusted EBITDA, as defined.

​

Adjusted Diluted EPS

​... (truncated)the inclusion of potentially dilutive stock awards and warrants excluded from GAAP diluted shares due to a net loss position, but do not include stock awards or warrants that are out of the money and whose inclusion would be antidilutive. We believe Adjusted Diluted EPS is useful to investors because it facilitates period-to-period comparisons of our earnings performance by excluding the effects of our pre-IPO preferred stock and other items that we do not consider indicative of our ongoing operating performance.

​

GMR Contacts:

Media Contact:

Kirsten Gurmendi

Public Relations Director, GMR Solutions Inc. media@gmr.net

877.418.2980

Investor Contact:

Krister Sorensen

Vice President, Investor Relations, GMR Solutions Inc.

Investor.relations@gmr.net

​⁶

​

GMR Solutions Inc. and Subsidiaries

Condensed Consolidated Balance Sheets

September 30, 2026 and December 31, 2025

(Amounts in thousands, except share and par value amounts)

​

​

​⁷

​

GMR Solutions Inc. and Subsidiaries

Condensed Consolidated Statements of Operations

For the three and nine months ended September 30, 2026 and 2025

(

Amounts in thousands, except share and per share amounts, unaudited)

​

​

​⁸

​

GMR Solutions Inc. and Subsidiaries

Condensed Consolidated Statements of Cash Flows

For the nine months ended September 30, 2026 and 2025

(Amounts in thousands, unaudited)

​⁹

​

GMR Solutions Inc. and Subsidiaries

Reconciliation of EBITDA and Adjusted EBITDA

For the three and nine months ended September 30, 2026 and 2025

(Amounts in thousands, unaudited)

The following table reconciles net income to EBITDA and Adjusted EBITDA:

​ nm – Not meaningful

​

​

​

​

​¹⁰

​

​

​

​

​

​

​

​

​

​

​

​

​¹¹

​

​

GMR Solutions Inc. and Subsidiaries

Reconciliation of Weighted-Average Common Shares Outstanding Used in Diluted EPS and Adjusted Diluted EPS

(Unaudited)

​

Reconciliation of Diluted Net Income (Loss) Available to Common Stockholders per Share to Adjusted Diluted EPS

(Unaudited)

​

​¹²

​

​

​

​

​

​¹³

​

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · GMR Solutions earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.